WT1 and ovarian cancer: These include: Muc16-targeting CAR T-cells armored with BiTEs against a peptide derived from the intracellular TAA Wilms tumor 1 (WT1), which demonstrated improved efficacy in ovarian cancer models with low Muc16 expression (155); and GPC3-targeting CAR T-cells that secrete BiTEs against B7-H3, which showed enhanced cytotoxicity against HCC cell lines with heterogeneous expression of GPC3 and B7-H3, although this was demonstrated only in vitro (156).